Adaptimmune Therapeutics PLC — Director's Dealing 2018

Mar 23, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2018-03-20

Reporting Person: Rawcliffe Adrian (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-20	Ordinary Shares	S	600000	$1.71	Disposed	0	Direct

Footnotes

F1: The Ordinary Shares whose sale is reported on this line are represented by American Depositary Shares ("ADSs"). Each ADS represents six Ordinary Shares. The Ordinary Shares were obtained from the partial exercise of an option that was granted on March 16, 2015.

F2: The sale price of $1.71 per Ordinary Share was derived from the sale price of $10.27 per ADS on March 20, 2018 divided by six.